| HS Code | 882103 |
| Product Name | D-Phenylglycine Methyl Ester Hydrochloride |
| Synonyms | (R)-Methyl 2-amino-2-phenylacetate hydrochloride |
| Cas Number | 19883-41-1 |
| Molecular Formula | C9H12ClNO2 |
| Appearance | white crystalline powder |
| Melting Point | 190-192 °C |
| Optical Rotation | [α]20/D = -118° (c=1, methanol) |
| Purity | ≥98% |
| Solubility | soluble in water, methanol, and ethanol; sparingly insoluble in ether |
| Storage Conditions | store sealed in a cool, dry, well-ventilated place at 2-8°C |
| Sensitivity | moisture sensitive |
As an accredited D-phenylglycine Methyl Ester Hydrochloride factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 25 g of D-phenylglycine Methyl Ester Hydrochloride in an amber glass bottle with a sealed polypropylene cap. |
| Container Loading (20′ FCL) | 20′ FCL: one full 20-foot container loaded with D-phenylglycine Methyl Ester Hydrochloride, properly packed in sealed drums, secure and ready for shipment. |
| Shipping | D-phenylglycine Methyl Ester Hydrochloride should be shipped in sealed, moisture-resistant containers to prevent hydrolysis. Keep away from strong oxidizing agents and acidic/basic materials. Store at ambient temperature, protected from heat and humidity. Standard non-hazardous transport is acceptable; ensure proper labeling and handling to avoid inhalation or skin contact. |
| Storage | Store D-phenylglycine Methyl Ester Hydrochloride in a tightly sealed container, protected from light and moisture, in a cool, dry, well-ventilated area. Keep away from oxidizing agents and strong bases. Maintain room temperature, ideally 2–8°C for prolonged stability. Ensure the container is desiccated after each use and handled under dry conditions to prevent hydrolysis or caking. |
| Shelf Life | Store in a cool, dry place in an airtight container. Stable for up to 2 years when stored unopened and protected from moisture. |
In semisynthetic β-lactam production, D-phenylglycine methyl ester hydrochloride (D-PGME·HCl; CAS 19883-41-1) functions as the activated side-chain donor in kinetically controlled acyl transfer to 6-aminopenicillanic acid (6-APA) and 7-aminodeacetoxycephalosporanic acid (7-ADCA). The hydrochloride salt improves aqueous solubility and permits direct pH-stat operation in immobilized penicillin G acylase reactors. Industrial compliance is governed by ICH Q7 Chapter 9 for API process controls and Ph. Eur. 10.0 monographs for ampicillin trihydrate and cephalexin monohydrate; residual solvent verification follows USP <467>. Typical addition stoichiometry ranges from 2.0:1 to 3.5:1 molar equivalents of D-PGME·HCl to the β-lactam nucleus, with substrate loading of 200–500 mM referenced to aqueous phosphate buffer at pH 6.3–6.8 and temperature 20–25 °C. Downstream processing uses a jacketed stirred-tank reactor with an external ultrafiltration loop (10 kDa cut-off) to retain immobilized enzyme; after 4–10 h, the reaction mixture is clarified, pH-adjusted to 4.5–5.0 to precipitate residual side chain, and the filtrate is concentrated before crystallization. The terminal finished product types are ampicillin trihydrate API and cephalexin monohydrate API for subsequent sterile formulation. Process failure is observed when the synthesis/hydrolysis ratio falls below 2.0, resulting in excessive D-phenylglycine formation and lower yield.
| Parameter | Setpoint |
|---|---|
| pH-stat control range | 6.3–6.8 |
| Reaction temperature | 20–25 °C |
| D-PGME·HCl to nucleus molar ratio | 2.0:1–3.5:1 |
| Substrate loading | 200–500 mM |
| Ultrafiltration membrane cut-off | 10 kDa |
| Reaction duration | 4–10 h |
Chemical acylation of 6-APA with D-phenylglycine methyl ester hydrochloride requires prior activation to D-phenylglycyl chloride hydrochloride. The hydrochloride salt of the methyl ester is suspended in dichloromethane and reacted with phosphorus pentachloride at -10 to 0 °C. A molar ratio of 1.0:1.1 substrate to PCl5 is maintained to achieve complete conversion to the acyl chloride without excessive anhydride formation. The resulting D-phenylglycyl chloride hydrochloride is coupled to 6-APA at 0–5 °C in aqueous acetone with simultaneous pH control using triethylamine; the addition ratio is 1.0–1.2 molar equivalents of acyl chloride per equivalent of 6-APA. This unit operation is executed in glass-lined reactors equipped with vacuum-controlled HCl removal and a dosing system for solid PCl5; batch-to-batch variance is observed when the reactor headspace relative humidity exceeds 60%, which hydrolyzes the acid chloride. Compliance standards include ICH Q3D for elemental impurities, USP <467> for dichloromethane (Class 2 residual solvent, limit 600 ppm), and ICH Q7 Chapter 9 for in-process control of chloride content. Downstream production proceeds through extraction, aqueous bicarbonate washing, and crystallization from water/acetone mixtures to yield ampicillin trihydrate. The terminal finished product type is non-sterile ampicillin trihydrate API used in oral suspension and injectable formulations.
For non-chromophoric racemic carboxylic acid APIs, D-phenylglycine methyl ester hydrochloride is converted to the free amine and coupled to the carboxyl group to create diastereomeric amides for reversed-phase HPLC determination of enantiomeric purity. The derivatization reaction follows ICH Q6A Decision Tree #1 for stereoisomeric purity and is executed under USP <621> chromatographic system suitability criteria. Formulation addition ratio: the free amine is added at 1.5–3.0 molar equivalents relative to the racemic acid analyte; 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide is added at 1.2 molar equivalents; and the reaction proceeds in acetonitrile/0.1 M phosphate buffer pH 6.8 at 20–25 °C for 45 min. The downstream analytical process uses a 250 × 4.6 mm C18 column with 5 μm particles, UV detection at 254 nm, and a mobile phase of methanol/20 mM phosphate buffer (55:45 v/v) at 1.0 mL/min. Diastereomeric separation factors of α ≥ 1.05 are achieved for arylpropionic acid derivatives under these conditions. The terminal finished product type is an enantiomeric purity/assay report for chiral API batch release and stability studies. Operational boundaries include the need to remove urea by-product from the coupling reagent before injection to avoid column fouling.
| Parameter | Setpoint |
|---|---|
| Column | 250 × 4.6 mm C18, 5 μm |
| Detection wavelength | 254 nm |
| Mobile phase | methanol/20 mM phosphate buffer pH 6.8, 55:45 v/v |
| Flow rate | 1.0 mL/min |
| Derivatizer stoichiometry | 1.5–3.0 molar equivalents |
| Coupling reagent | 1.2 molar equivalents |
Reduction of the methyl ester to D-phenylglycinol is the first unit operation in the preparation of 4-phenyl-2,2-dimethyloxazolidine chiral auxiliaries. The hydrochloride salt is charged into anhydrous tetrahydrofuran at 0–5 °C, and lithium aluminium hydride is added at 1.0–1.5 molar equivalents per equivalent of ester under nitrogen. The reaction is maintained below 20 °C to control the exotherm and prevent racemization of the benzylic stereocenter. The reduction is governed by ICH Q3C for residual tetrahydrofuran (Class 2 solvent, limit 720 ppm in the isolated amino alcohol) and USP <467> for solvent verification. Downstream work-up uses sequential addition of water/15% NaOH and filtration of aluminium salts; the filtered D-phenylglycinol is then condensed with pivalaldehyde at 1.0–1.1 molar equivalents in cyclohexane with azeotropic water removal. This auxiliary is used in asymmetric α-alkylation of N-acyl derivatives. The terminal finished product type is 4-phenyl-2,2-dimethyloxazolidine chiral auxiliary, supplied as a single stereoisomer for asymmetric synthesis campaigns. Process controls are batch-specific due to the sensitivity of lithium aluminium hydride reductions to trace moisture; residual moisture in the methyl ester feed must be below 0.1% w/w.
Where preparative resolution of racemic arylpropionic acid derivatives is required, D-phenylglycine methyl ester hydrochloride is neutralized with aqueous sodium carbonate and used as a basic resolving agent for diastereomeric salt formation. Compliance for the resolution step is aligned with ICH Q7 Chapter 9 and USP <1174> for process validation. Formulation addition ratio: the resolved acid is charged at 1.0 molar equivalent, and the neutralized resolving agent is added at 0.5–1.1 molar equivalents depending on whether the acid is racemic or partially enriched; solvent systems such as isopropanol/water (85:15 v/v) are used at 40 °C to dissolve the salt, then cooled to 0–5 °C for crystallization. Downstream production uses a temperature-controlled crystallizer with controlled cooling rate 0.5 °C/min and seed crystals of the target diastereomeric salt; recrystallization is repeated until the diastereomeric excess exceeds 99.0%. The terminal finished product type is enantiopure arylpropionic acid intermediate after acidic salt decomposition. Published data for the exact diastereomeric salt separation for every substrate is limited; process ratios are adjusted based on solubility phase diagrams.
In cephalexin monohydrate manufacturing, D-phenylglycine methyl ester hydrochloride is activated to the corresponding acyl chloride and coupled to 7-ADCA. Solvent selection and polymorphic control define the commercial robustness of this process. The acylation is operated at 0–5 °C in a dichloromethane/water two-phase system with pH-stat addition of triethylamine to maintain pH 6.5–7.0. Addition ratio for the acyl chloride to 7-ADCA is 1.2–1.5:1; the excess side chain is hydrolyzed during subsequent aqueous extraction. Compliance anchors are ICH Q3C for dichloromethane (Class 2, 600 ppm) and Ph. Eur. 10.0 cephalexin monohydrate monograph; ICH Q7 Chapter 11 governs quarantine and reprocessing of non-conforming polymorph batches. Downstream processing uses a seed-bed crystallizer charged with 1–5% w/w cephalexin monohydrate seed crystals and a slow pH shift from 2.5 to 4.5 at 30–35 °C to promote the desired monohydrate polymorph. The terminal finished product type is cephalexin monohydrate API for oral dosage forms. Batch failure modes observed in manufacturing include oiling-out when the crystallization pH gradient exceeds 0.2 pH units/min.
Competitive D-phenylglycine Methyl Ester Hydrochloride prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
D-Phenylglycine methyl ester hydrochloride, identified by CAS 19883-41-1 and molecular formula C9H11NO2·HCl, is the hydrochloric acid salt of the methyl ester of (R)-2-amino-2-phenylacetic acid. The material is supplied as a white to off-white crystalline powder with a formula weight of 201.65 g mol⁻¹. Commercial designations include D-PG-OMe·HCl and (R)-phenylglycine methyl ester hydrochloride; the salt is preferred over the free amino ester in multistep synthesis because it remains free-flowing and less colour-sensitive at 25 °C and 50% RH. The theoretical chloride content of the salt is 17.6% w/w, and the amino centre is present as the protonated hydrochloride, which means the free amine must be released in situ before acylation.
At ambient storage, the salt is stable in tightly closed containers. Long-term retention at 2–8 °C can be used to preserve chiral integrity, but published data for holding beyond 36 months are limited; open containers above 60% RH pick up water and may require vacuum drying at 40–50 °C. The compound is freely soluble in water and methanol, partially soluble in ethanol, and only sparingly soluble in ethyl acetate after basification. In process design, this solubility profile permits aqueous extraction of the hydrochloride at pH 2–4, while the free base partitions into ethyl acetate at pH 8–9 with a target contact time not exceeding 30 min to limit base-catalysed racemization.
Configuration is the primary difference from the L-isomer. L-phenylglycine methyl ester hydrochloride has the opposite sign of optical rotation and is used when the target requires an (S)-α-amino acid motif; the D-isomer is specified for (R)-configured intermediates. Chiral HPLC on a polysaccharide chiral stationary phase with hexane/2-propanol containing 0.1% triethylamine separates the D- and L-forms, and a typical release lot shows ≥ 99.0% enantiomeric excess. The two enantiomers have essentially identical molecular weight and solubility, so process equipment is interchangeable, but a chiral method must be used to verify identity after precipitation or recrystallization.
Compared with D-4-hydroxyphenylglycine methyl ester hydrochloride, the present compound lacks the para-hydroxy substituent. This difference reduces aqueous solubility at basic pH and removes the need to protect a phenolic oxygen during oxidations or esterifications. Consequently, the non-hydroxylated methyl ester is less polar and tends to crystallise more readily from ethyl acetate/hexane; the 4-hydroxy analog more often requires saline aqueous workup or methanolic recrystallization. In coupling reactions, the phenolic group of the 4-hydroxy analog can compete as an oxygen nucleophile if not protected, whereas the phenylglycine methyl ester hydrochloride carries only the amino centre as a reactive site.
N-Boc-D-phenylglycine methyl ester is not a process-equivalent product. The Boc group blocks the amine, so the material is used after acidic deprotection, most commonly with trifluoroacetic acid in dichloromethane. By contrast, the hydrochloride does not require an acidic deprotection step; it is neutralised with a tertiary amine immediately before coupling. Using the hydrochloride in a protocol designed for the N-Boc material would leave a protonated amine and lead to incomplete acylation, while using the N-Boc material in a direct coupling protocol without deprotection yields no new amide bond.
The lot release specification for peptide-grade material combines chemical, optical, and residual-solvent controls. Total assay alone is insufficient because non-chiral impurities can co-elute on standard reversed-phase HPLC; enantiomeric excess and residual water are required to prevent false confidence in downstream optical purity.
| Parameter | Typical control range | Procedure or standard |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual inspection |
| Assay by HPLC at 220 nm | ≥ 98.0% on dried basis | C18 reversed-phase HPLC |
| Enantiomeric excess | ≥ 99.0% | Chiral HPLC |
| Specific rotation [α]D20 | -117° ± 2° (c = 1, H2O) | USP <781> |
| Water content | ≤ 0.5% | ASTM E203-21 |
| Residue on ignition | ≤ 0.1% | USP <281> |
| Related substances | Total ≤ 1.0% | HPLC area percent |
The chiral release method uses a 150 mm × 4.6 mm amylose-based analytical column with a mobile phase of hexane/2-propanol/triethylamine 80:20:0.1 at 0.8 mL min⁻¹. Under these conditions, the L-isomer is baseline-resolved from the D-isomer; exact relative retention times are column-specific. A mass spectrometric identity check is not sufficient to distinguish the enantiomers because they produce identical fragmentation patterns.
Residual methanol is controlled to ≤ 3000 ppm, consistent with ICH Q3C Option 2; the limit is derived from a permitted daily exposure of 30 mg day⁻¹. Residual water is measured by ASTM E203-21 Karl Fischer titration. For moisture-sensitive activation, if water content exceeds 0.3%, the lot is dried under vacuum at 40–50 °C for 4 h and re-tested before charging to an acid chloride or mixed anhydride reactor.
For continuous downstream use, particle size is a processing boundary. A lot with a d50 near 120 μm and fines below 15% through 75 μm feeds uniformly from a loss-in-weight dosing unit. If moisture-induced caking raises aggregate size above 2 mm, a rotary lump breaker with 0.5 mm mesh is installed before the feed hopper. Because the salt contains 17.6% chloride, 316L stainless-steel contact surfaces are preferred; wet cake should not be held in carbon steel pans under ambient humidity because chloride can initiate pitting.
The α-carbon of the phenylglycine is stereogenic and activated by the adjacent ester and aryl groups. Racemization is base-catalysed via a deprotonation-reprotonation sequence; therefore, aqueous workup is maintained below pH 8.5. In coupling reactions, the tertiary amine is charged at 0–5 °C and the free amine is acylated promptly to avoid α-deprotonation. Holding the free base in solution for more than 30 min at 20 °C under basic conditions can erode enantiomeric purity and hydrolyse the methyl ester.
The methyl ester hydrochloride is selected when the route requires an unprotected α-amino acid methyl ester that must be stored as a stable crystalline solid. The free base is not the preferred shipment form because it is more hygroscopic and may undergo discoloration or methyl ester hydrolysis during transport. In solution-phase coupling, the salt is neutralised with 1.0–1.1 equivalents of triethylamine or N-methylmorpholine; this releases the free amine in situ. The methyl ester remains intact during carbodiimide-mediated couplings but is removed by saponification with lithium hydroxide at 0–5 °C when the free acid is required.
The hydrochloride is not suitable for direct use in non-neutralised form with electrophilic acylation reagents; if the tertiary amine charge is omitted, the protonated amino group does not function as a nucleophile and the reaction stalls at low conversion. In such a case, the residual starting material can be recovered from the aqueous layer at pH 2–4 as the hydrochloride. The chloride counterion is incompatible with silver salts because silver chloride precipitates and fouls filter cloths; it should also be excluded from cyanide, strong oxidising acid, and peroxymonosulfate process streams.
Compared with the ethyl ester hydrochloride, the methyl ester is less sterically hindered and more easily hydrolysed; this is advantageous when deprotection is desired after coupling, but it is a liability when hot alkaline workup is required. Methyl ester hydrolysis by-products are also more volatile than ethyl ester by-products, simplifying solvent recovery by distillation. The ethyl analog may be selected for more hydrophobic intermediates, but its hydrolysis in water/tetrahydrofuran at pH 10 and 25 °C proceeds on a longer timescale.
In a pilot-scale coupling campaign, a 100 L glass-lined reactor is charged with dimethylformamide and the hydrochloride. Nitrogen blanketing is used, and the jacket is held at 0–5 °C during the addition of N-methylmorpholine. The resulting suspension is aged for 30 min before the activated acid solution is fed. Agitation at 120–180 rpm is used to disperse the exotherm; the addition rate is controlled so the internal temperature does not exceed 10 °C. Following reaction, the mixture is quenched with dilute hydrochloric acid and extracted with ethyl acetate.
Drying of the wet product on a vacuum tray dryer uses a bed depth of 2–3 cm at 45 °C and 200 mbar absolute pressure for 6–8 h. The vacuum pump is protected by a cold trap because traces of methyl ester can volatilise. Drying above 60 °C is not recommended because the salt may discolour and residual moisture can accelerate ester hydrolysis. The dried material is passed through a 0.5 mm rotary sieve before packaging.
In β-lactam side-chain precursor synthesis, D-phenylglycine methyl ester hydrochloride is used as a chiral building block where the methyl ester protects the carboxyl terminus during amide formation. The hydrochloride is not a direct replacement for D-4-hydroxyphenylglycine methyl ester hydrochloride in amoxicillin-related side chains because the para-hydroxy group changes hydrogen-bonding and aqueous solubility. Published data for this specific configuration in amoxicillin side-chain assembly is limited. Process-scale work with the non-hydroxylated compound generally uses the hydrochloride for crystallinity and storage stability, and the free amine is generated in the reactor immediately before the coupling step. In a typical route, the salt is dissolved in dimethylacetamide, neutralised with N-methylmorpholine at 0–5 °C, and converted to an activated intermediate such as a mixed anhydride; after coupling, the methyl ester is saponified with lithium hydroxide at 0–5 °C and the product is isolated by acidification to pH 2–3.